vorinostat and vx680
vorinostat has been researched along with vx680 in 8 studies
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Soverini, S | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Nguyen, TK; Pei, XY; Venditti, CA | 1 |
| Balusu, R; Bhalla, K; Buser, CA; Chen, J; Eaton, K; Fiskus, W; Jillella, A; Joshi, R; Kolhe, R; Lee, P; Peiper, S; Rao, R; Ustun, C; Wang, Y; Yang, Y | 1 |
| Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Dino, PM; Forman, SJ; Jove, R; Kirschbaum, MH; Kowolik, CM; Kretzner, L; Scuto, A; Ventura, P; Wu, J; Yen, Y | 1 |
| Giardina, C; Kuratnik, A; Mellone, BG; Senapati, VE; Vella, AT; Verma, R | 1 |
| Balusu, R; Bhalla, KN; Fiskus, W; Hembruff, SL; Peiper, SC; Peth, K; Rao, R; Sharma, P; Smith, JE; Venkannagari, S | 1 |
Other Studies
8 other study(ies) available for vorinostat and vx680
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat | 2007 |
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aurora Kinase A; Aurora Kinases; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Vorinostat | 2008 |
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Fusion Proteins, bcr-abl; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Microtubule-Associated Proteins; Mutation; Neoplasm Proteins; Piperazines; Survivin; Vorinostat | 2008 |
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Topics: Adult; Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Vorinostat | 2010 |
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cyclohexanecarboxylic Acids; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, myc; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Lymphoma; MicroRNAs; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Telomerase; Thiazoles; Vorinostat | 2011 |
Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.
Topics: Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Butyrates; Colonic Neoplasms; Cytokines; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred Strains; Piperazines; Prophase; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vorinostat | 2012 |
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Gene Dosage; Gene Expression; Gene Knockdown Techniques; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Piperazines; Protein Binding; Protein Serine-Threonine Kinases; RNA Interference; Survivin; Vorinostat; Xenograft Model Antitumor Assays | 2012 |